Epigral Limited will host a conference call on July 27, 2026, at 5:00 PM IST to discuss its financial performance for the first quarter of FY27. The announcement was made in reference to Regulation 30 and Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The call provides an opportunity for investors and analysts to gain insights directly from the company's leadership regarding the quarterly results.

The discussion will be led by Epigral Limited 's senior management team. Participants include Maulik Patel, Chairman and Managing Director; Kaushal Soparkar, Executive Director; Rakesh Agrawal, Chief Financial Officer; and Milind Kotecha, Investor Relations and Strategy. The session is being coordinated by Emkay Global Financial Services Ltd.

Conference Call Details

The event is scheduled for Monday, July 27, 2026. Participants are advised to pre-register to avoid wait times and use the Express Join feature with DiamondPass™. The access details are outlined below:

International toll-free numbers have been arranged for various regions including the USA, UK, Singapore, Australia, and Japan, among others. For specific regional numbers, investors should refer to the official invitation. Further inquiries can be directed to Sabri Hazarika at Emkay Global Financial Services Ltd.

Epigral has incorporated a wholly owned subsidiary, Epigral Advanced Materials Limited, on July 7, 2026, to expand its manufacturing capabilities in the chemicals sector. The new entity has been established with a paid-up capital of ₹1,00,000, comprising 10,000 equity shares of ₹10 each. This strategic move aims to strengthen the company's presence in the advanced chemicals segment within India.

Subsidiary Details

Epigral Advanced Materials Limited is registered as a wholly owned subsidiary of Epigral Limited, making it a related party. The incorporation follows Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The subsidiary's primary objective is the manufacturing of chemicals, aligning with Epigral's broader business focus.

The consideration for the subscription was settled in cash. No specific governmental or regulatory approvals were required for the incorporation, as indicated in the filing submitted to the National Stock Exchange of India Limited and BSE Limited.